Ipsen

Ipsen is a global biopharmaceutical company based in Paris, France, focused on developing and commercializing transformative medicines in oncology, rare diseases, and neuroscience to address high unmet medical needs for patients. The company maintains a global presence with approximately 5,000 employees and its pharmaceutical products registered in over 88 countries worldwide, ensuring broad access to its specialty care therapies. Ipsen strategically expands its therapeutic portfolio through targeted acquisitions, such as Epizyme, which brought Tazverik for follicular lymphoma, and Clementia Pharmaceuticals for rare bone disease drug candidates. In 2022, the company divested its Consumer HealthCare division to Mayoly Spindler, streamlining its focus on specialty care. The organization originated in 1929 as Beaufour Laboratories, founded by Dr. Henri Beaufour, with the Ipsen subsidiary formally established in 1975.